This clinical trial is focused on studying the effects of a medication called bimekizumab in adults with psoriatic arthritis. Psoriatic arthritis is a condition that causes joint pain and swelling, often associated with the skin condition psoriasis. The study aims to compare how well bimekizumab works against another medication called risankizumab, which is also used to treat this condition.
Participants in the study will receive either bimekizumab, risankizumab, or a placebo, which is a substance with no active medication. The medications are given as injections under the skin. The study will last for about 24 weeks, with the main focus on the first 16 weeks to see how effective the treatments are. During this time, participants will have regular check-ups to monitor their health and the effects of the medication.
The purpose of the study is to evaluate the safety and effectiveness of bimekizumab in treating active psoriatic arthritis. Participants will be closely monitored for any side effects or changes in their condition. The study will help determine if bimekizumab is a better treatment option compared to risankizumab for people with this condition.
1joining the study
Upon joining the study, you will be randomly assigned to receive either the investigational medication bimekizumab or the comparator medication risankizumab. This process is double-blind, meaning neither you nor the study team will know which medication you are receiving.
2medication administration
You will receive the medication through a method called subcutaneous use, which means it is injected under the skin. The specific dosage and frequency of administration will be determined by the study protocol and communicated to you by the study team.
3treatment duration
The treatment will last for a period of 16 weeks. During this time, you will continue to receive the assigned medication according to the schedule provided by the study team.
4monitoring and assessments
Throughout the study, you will undergo regular assessments to monitor your health and the effects of the medication. These assessments may include physical examinations, blood tests, and questionnaires about your symptoms and overall well-being.
5end of treatment evaluation
At the end of the 16-week treatment period, you will have a final evaluation to assess the effectiveness and safety of the medication. This will include measuring your response to treatment using criteria such as the American College of Rheumatology 50 (ACR50) and other relevant health indicators.
Who Can Join the Study?
Participants must have a documented diagnosis of adult-onset Psoriatic Arthritis (PsA) for at least 6 months before joining the study. Psoriatic Arthritis is a type of arthritis that affects some people with the skin condition psoriasis.
Participants must have active Psoriatic Arthritis, meaning they still have symptoms despite previous treatment with certain medications like csDMARD (conventional synthetic disease-modifying antirheumatic drugs) or apremilast.
Participants must have at least 3 tender joints and 3 swollen joints at the start of the study. Tender joints are those that hurt when touched, and swollen joints are those that are larger than normal due to inflammation.
Participants must have at least one active psoriatic skin lesion or a history of chronic plaque-type psoriasis, which is a common form of psoriasis characterized by raised, red patches covered with a silvery white buildup of dead skin cells.
Participants may currently be taking csDMARD therapy and must have tried at least one csDMARD in the past, such as methotrexate, leflunomide, or sulfasalazine. They must have stopped using it because it didn’t work well enough or they couldn’t tolerate it.
Participants can either be new to bDMARD (biological disease-modifying antirheumatic drugs) or have used no more than one TNFα inhibitor in the past. TNFα inhibitors are a type of medication that reduces inflammation by blocking a protein called tumor necrosis factor alpha.
If participants have used a TNFα inhibitor before, they must not have stopped using it due to financial or insurance reasons. They must have either not responded well to the treatment after at least 3 months or had side effects that made them stop using it.
Participants must be adults, as the study is for adult-onset Psoriatic Arthritis.
Both male and female participants are eligible for the study.
Who Cannot Join the Study?
Patients who do not have psoriatic arthritis cannot participate.
Patients who are not within the specified age range cannot participate.
Patients who are part of a vulnerable population cannot participate.
Bimekizumab is a medication being studied for its potential to help people with active psoriatic arthritis, a condition that causes joint pain and skin problems. It works by targeting specific proteins in the body that are involved in inflammation, which is a key part of psoriatic arthritis. By reducing inflammation, bimekizumab may help to relieve symptoms such as joint pain and swelling, and improve the skin condition associated with this disease.
Risankizumab is another medication used in this study for people with active psoriatic arthritis. Like bimekizumab, it aims to reduce inflammation by targeting certain proteins in the body. This can help to decrease joint pain and swelling, as well as improve skin symptoms. The study is comparing risankizumab to bimekizumab to see which one is more effective in treating the symptoms of psoriatic arthritis after 16 weeks of treatment.
Psoriatic arthritis – Psoriatic arthritis is a chronic inflammatory disease that affects the joints and skin. It is associated with psoriasis, a condition that causes red, scaly skin patches. The disease can cause joint pain, stiffness, and swelling, often affecting fingers and toes. Over time, it can lead to joint damage and deformities if not managed. The progression of psoriatic arthritis can vary, with periods of increased symptoms and times of remission. It can also affect other parts of the body, including the eyes and nails.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Bulgaria 
Czechia 
Germany 
Hungary 
Poland 
Spain